Browsing NTNU Open by Author "Waage, Anders"

Now showing items 21-40 of 49

    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma 

      Went, Molly; Sud, Amit; Försti, Asta; Halvarsson, Britt-Marie; Weinhold, Niels; Kimber, Scott; van Duin, Mark; Thorleifsson, Gudmar; Holroyd, Amy; Johnson, David C.; Li, Ni; Orlando, Giulia; Law, Philip J.; Ali, Mina; Chen, Bowang; Mitchell, Jonathan S.; Gudbjartsson, Daniel F.; Kuiper, Rowan; Stephens, Owen W.; Bertsch, Uta; Broderick, Peter; Campo, Chiara; Bandapalli, Obul R.; Einsele, Hermann; Gregory, Walter A.; Gullberg, Urban; Hillengass, Jens; Hoffmann, Per; Jackson, Graham H.; Jöckel, Karl-Heinz; Johnsson, Ellinor; Kristinsson, Sigurður Y.; Mellqvist, Ulf-Henrik; Nahi, Hareth; Easton, Douglas; Pharoah, Paul; Dunning, Alison; Peto, Julian; Canzian, Federico; Swerdlow, Anthony; Eeles, Rosalind A.; Kote-Jarai, ZSofia; Muir, Kenneth; Pashayan, Nora; Nickel, Jolanta; Nöthen, Markus M.; Rafnar, Thorunn; Ross, Fiona M.; da Silva Filho, Miguel Inacio; Thomsen, Hauke; Turesson, Ingemar; Vangsted, Annette; Andersen, Niels Frost; Waage, Anders; Walker, Brian A.; Wihlborg, Anna-Karin; Broyl, Annemiek; Davies, Faith E.; Thorsteinsdóttir, Unnur; Langer, Christian; Hansson, Markus; Goldschmidt, Hartmut; Kaiser, Martin; Sonneveld, Pieter; Stefansson, Kari; Morgan, Gareth J.; Hemminki, Kari; Nilsson, Björn; Houlston, Richard S. (Journal article; Peer reviewed, 2018)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...

    • Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients 

      Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)
      Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ...

    • Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2020)
      Population‐based studies from high‐quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry ...

    • Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells 

      Starheim, Kristian Kobbenes; Holien, Toril; Misund, Kristine; Johansson, Ida; Baranowska, Katarzyna Anna; Sponaas, Anne Marit; Hella, Hanne; Buene, Glenn; Waage, Anders; Sundan, Anders; Bjørkøy, Geir (Journal article; Peer reviewed, 2016)
      Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, ...

    • Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells 

      Aass, Kristin Roseth; Mjelle, Robin; Kastnes, Martin Haugrud; Tryggestad, Synne Stokke; van den Brink, Luca M; Roseth, Ingrid Aass; Westhrin, Marita; Zahoor, Muhammad; Moen, Siv Helen; Nedal, Tonje Marie Vikene; Buene, Glenn; Misund, Kristine; Sponaas, Anne-Marit; Ma, Qianli; Sundan, Anders; Groen, Richard WJ; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese (Journal article; Peer reviewed, 2021)
      Interleukin-32 (IL-32) is a nonclassical cytokine expressed in cancers, inflammatory diseases, and infections. Its expression is regulated by two different oxygen sensing systems; HIF1α and cysteamine dioxygenase (ADO), ...

    • Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial 

      Sonja Zweegman, Zweegman; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson; Trung Hieu Do, Hieu; Dorota Knut-Bojanowska, Knut-Bojanowska; Ellen van der Spek, van; Asta Svirskaite, Svirskaite; Anja Klostergaard, Klostergaard; Morten Salomo, Salomo; Celine Blimark, Blimark; Paula F Ypma, F; Ulf-Henrik Mellqvist, Mellqvist; Pino J Poddighe, J; Marian Stevens-Kroef, Stevens-Kroef; Niels W C J van de Donk, W; Pieter Sonneveld, Sonneveld; Markus Hansson, Hansson; Bronno van der Holt, van; Niels Abildgaard, Abildgaard (Peer reviewed; Journal article, 2020)

    • Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma 

      Lund, Johan; Gruber, Astrid; Lauri, Birgitta; Duru, Adil Doganay; Blimark, Cecilie; Swedin, Agneta; Hansson, Markus; Forsberg, Karin; Ahlberg, Lucia; Carlsson, Conny; Waage, Anders; Gimsing, Peter; Vangsted, Annette Juul; Frølund, Ulf; Holmberg, Erik; Gahrton, Gösta C.A.; Alici, Evren; Hardling, Mats; Mellqvist, Ulf-Henrik; Nahi, Hareth (Journal article; Peer reviewed, 2018)
      Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once ...

    • Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia – Follow-up of the RITP study 

      Tjønnfjord, Eirik; Holme, Pål Andre; Darne, Bernadette; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Romdhan, Neila Ben; Ghanima, Waleed Khalid (Peer reviewed; Journal article, 2020)
      RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, ...

    • Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial 

      Schmitz, Alexander; Brøndum, Rasmus Froberg; Johnsen, Hans Erik; Mellqvist, Ulf-Henrik; Waage, Anders; Gimsing, Peter; Op Bruinink, Davine Hofste; van der Velden, Vincent; van der Holt, Bronno; Hansson, Markus; Andersen, Niels Frost; Frølund, Ulf Christian; Helleberg, Carsten; Schjesvold, Fredrik Hellem; Ahlberg, Lucia; Gulbrandsen, Nina; Andreasson, Bjorn; Lauri, Birgitta; Haukås, Einar; Bødker, Julie Støve; Roug, Anne Stidsholt; Bøgsted, Martin; Severinsen, Marianne T.; Gregersen, Henrik; Abildgaard, Niels; Sonneveld, Pieter; Dybkær, Karen (Peer reviewed; Journal article, 2022)
      Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer ...

    • Marevan® som sekundær VTE-profylakse 

      Nesje, Øyvind Vestermo; Vik, Alexander Berge (Master thesis, 2013)
      Bakgrunn: 25-50% av venøse tromboembolismer (VTE) regnes som uprovoserte. Mange av disse pasientene er kandidater for livslang antikoagulasjonsbehandling. Nye retningslinjer for behandling av disse pasientene er i ferd med ...

    • Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report 

      Murray, David L.; Puig, Noemi; Kristinsson, Sigurður Y.; Usmani, Saad; Dispenzieri, Angela; Bianchi, Giada; Kumar, Shaji; Chng, Wee Joo; Hajek, Roman; Paiva, Bruno; Waage, Anders; Rajkumar, S. Vincent; Durie, Brian (Peer reviewed; Journal article, 2021)
      Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect ...

    • Monitoring multiple myeloma by quantification of recurrent mutations in serum 

      Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril; Standal, Therese; Børset, Magne; Beisvag, Vidar; Myklebost, Ola; Meza, Leonardo Zepeda; Hong, Yan Dai; Sundan, Anders; Waage, Anders (Journal article; Peer reviewed, 2017)
      Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term ...

    • Multiple myeloma in Norway - Population-based studies on incidence, survival, familial risk, and associated malignancies 

      Langseth, Øystein Olstad (Doctoral theses at NTNU;2022:110, Doctoral thesis, 2022)
      Norsk sammendrag Myelomatose utgjør omtrent 10% av all hematologisk kreft og karakteriseres av klonal proliferasjon av maligne plasmaceller i benmargen. Myelomatose utvikles fra et forstadium som kalles monoklonal gammopati ...

    • Multiple Myeloma-study of cellular sensitivity to proteasome inhibitors 

      Baranowska, Katarzyna Anna (Doctoral theses at NTNU;2018:273, Doctoral thesis, 2018)
      Myelomatose (benmargskreft) – en studie av kreftcellenes følsomhet for kreftmedisiner i gruppen proteasomhemmere Myelomatose er en kreftform som utvikler seg i beinmargen og karakteriseres av ukontrollert vekst av de ...

    • Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines 

      Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Peer reviewed; Journal article, 2022)
      Introduction: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...

    • MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy 

      Holien, Toril; Misund, Kristine; Olsen, Oddrun Elise; Baranowska, Katarzyna Anna; Buene, Glenn; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2015)
      In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary ...

    • Optimization and Validation of Digital Droplet PCR assays for Detection of circulating tumor DNA in serum/plasma from patients with Multiple Myeloma 

      Skytøen, Emilie Ranheim (Master thesis, 2017)
      Circulating tumor DNA (ctDNA) has been shown as a promising biomarker for monitoring several tumor types. We want to study the use of ctDNA in monitoring multiple myeloma, by use of digital droplet PCR (ddPCR). The objective ...

    • Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma 

      Aass, Kristin Roseth; Nedal, Tonje Marie Vikene; Tryggestad, Synne Stokke; Haukås, Einar; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese; Mjelle, Robin (Peer reviewed; Journal article, 2022)
      Multiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells that proliferate in the bone marrow. miRNAs are promising biomarkers for risk stratification in MM and several miRNAs are shown to have ...

    • Patterns of previous and secondary malignancies in patients with multiple myeloma 

      Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)
      Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ...

    • PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy 

      Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth; Waage, Anders; Sundan, Anders (Peer reviewed; Journal article, 2015)
      In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore ...